RT Journal Article
SR Electronic
T1 The Potential Contribution of Radiopharmaceutical Therapies in Managing Oligometastatic Disease
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP jnumed.123.266772
DO 10.2967/jnumed.123.266772
A1 Kishan, Amar U.
A1 Siva, Shankar
A1 Hofman, Michael S.
A1 Nagarajah, James
A1 Kiess, Ana P.
A1 Tran, Phuoc
A1 Calais, Jeremie
YR 2024
UL http://jnm.snmjournals.org/content/early/2024/02/15/jnumed.123.266772.abstract
AB There is a growing understanding of the oligometastatic disease state, characterized by the presence of 5 or fewer lesions. Advanced molecular imaging techniques, such as prostate-specific membrane antigen PET, refines the ability to detect oligometastatic recurrences (oligorecurrences) early. These developments have led to the exploration of metastasis-directed therapy (MDT) in oligorecurrent disease as an alternative to or as a means of delaying systemic therapy. Unfortunately, MDT often does not provide a durable cure, and progression—particularly progression in multiple new areas—remains a concern. Simultaneously, developments in radioligand therapy (RLT) have led to studies showing overall survival benefits with α-emitting and β-emitting RLT in advanced, high-volume, metastatic castration-resistant prostate cancer. The success of RLT in late-stage disease suggests that earlier use in the disease spectrum may be impactful. Specifically, integration of RLT with MDT might reduce progression, including polymetastatic progression, in the setting of oligorecurrent disease.